title: Individualizing care with injectable glucose-lowering agents.
abstract: Insulin and GLP-1R agonists are important treatment options for the management of patients with T2DM, yet provider and patient concerns limit their use. Effective strategies, including ongoing patient education, can be easily implemented to overcome concerns and streamline initiation and ongoing use of injectables. The use of a GLP-1R agonist, for example, is 1 strategy recommended when avoidance of hypoglycemia or weight gain is a specific treatment goal.
authors: Diabetes Nation, High Lakes Health Care, St. Charles Hospital, Bend, OR.
authors: Eden M
authors: EM
authors: Miller
mesh_terms: D000465:Algorithms; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced* / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007267:Injections; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018027:Receptors, Glucagon / Q000819:agonists*; D016896:Treatment Outcome
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D007328:Insulin; D018027:Receptors, Glucagon